Institution profile

医療法人社団福十 みたかヘルスケアクリニック

Explore the institution's name, address and registered technologies as published, along with plan classifications, score components and sources.

The ranking reflects only the registration data published by Japan's Ministry of Health, Labour and Welfare; it does not represent treatment outcomes or quality of care. Scoring method →

Source: Ministry of Health, Labour and Welfare public directory of regenerative medicine providers MHLW e-Regenerative Medicine public register · Directory archive date I: 2026-07-19 / II: 2026-09-26 / III: 2026-05-18 · Internet Archive

MHLW e-Regenerative Medicine public registerPublic document number 03C2501001 +4

Location

Prefecture
Tokyo
Address
三鷹市下連雀3-38-4 三鷹産業プラザ5F-B

Plan classification

  • Class INot registered
  • Class IINot registered
  • Class IIIThe low-risk category under the law.

Certified committee for regenerative medicine

  • 一般社団法人分子免疫学研究所 認定再生医療等委員会
  • 一般社団法人分子免疫学研究所認定再生医療委員会
  • がん免疫細胞療法審査委員会
  • +1

Public score

34.2/ 100

A · Review level
10.0 / 30
B · Technologies
20.6 / 35
C · Coverage
3.6 / 25
D · Class I / II technologies
0.0 / 10

The public score is calculated from public registration information and does not reflect quality of care. Scoring method →

Overall ranking

No. 1424of 1736

Registered technologies
5
Areas covered
1

Technology areas · Rank

Position in the overall score distribution

0–100 · Public score
000–9.9 · 0 institutions
01010–19.9 · 0 institutions
2172020–29.9 · 217 institutions
3163030–39.9 · 316 institutions
7564040–49.9 · 756 institutions
2465050–59.9 · 246 institutions
1326060–69.9 · 132 institutions
417070–79.9 · 41 institutions
248080–89.9 · 24 institutions
49090–100 · 4 institutions
This institution 34.2
Public score →100

Registered technologies (5)

NK and immune cells 5
Registered technologies · Japanese originalTechnology areasPlan classification
CTLを用いる、悪性新生物に対するCTL療法NK and immune cellsClass III
NK細胞を用いる、悪性新生物に対するANK自己リンパ球免疫療法NK and immune cellsClass III
NKT細胞活性化自己樹状細胞ワクチン療法NK and immune cellsClass III
自己樹状細胞ワクチン療法NK and immune cellsClass III
成分採血での悪性腫瘍の抑制及び治療のためのGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®)NK and immune cellsClass III

Certified committee for regenerative medicine

  • 一般社団法人分子免疫学研究所 認定再生医療等委員会
  • 一般社団法人分子免疫学研究所認定再生医療委員会
  • がん免疫細胞療法審査委員会
  • 日本薬事法務学会再生医療等委員会

Public document number

  • 03C2501001
  • 03C2501002
  • 02C2505021
  • 02C2507049
  • 02C2602017
Plan classification · Certified committee for regenerative medicine · Public document number
Registered technologiesPlan classificationCertified committee for regenerative medicinePublic document number
NKT細胞活性化自己樹状細胞ワクチン療法Class III一般社団法人分子免疫学研究所 認定再生医療等委員会03C2501001
自己樹状細胞ワクチン療法Class III一般社団法人分子免疫学研究所認定再生医療委員会03C2501002
NK細胞を用いる、悪性新生物に対するANK自己リンパ球免疫療法Class IIIがん免疫細胞療法審査委員会02C2505021
CTLを用いる、悪性新生物に対するCTL療法Class IIIがん免疫細胞療法審査委員会02C2507049
成分採血での悪性腫瘍の抑制及び治療のためのGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®)Class III日本薬事法務学会再生医療等委員会02C2602017

Other institutions in the same prefecture

← Institution directory
One-to-one advice

Still unsure? Ask an advisor

Use the “Chat with an advisor” button on this page (at the bottom of the screen on mobile, bottom right on desktop) to open a chat with the Stem Cell Japan advice desk. Consultation and coordination are free, and an advisor replies within one working day.

Chat with an advisor